华阳新材2025年度业绩快报深度解读
华阳新材发布2025年度业绩快报，亏损大幅收窄，资产处置收益显著
山西华阳新材料股份有限公司（600281）于2026年4月4日发布了2025年度业绩快报，向投资者披露了公司经营情况与财务数据。
一、业绩亮点与主要财务数据
- 营业收入实现两位数增长：2025年度公司实现营业总收入45,135.91万元，同比增长16.67%。
- 亏损显著收窄：归属于母公司所有者的净利润为-570.34万元，较上年同期的-18,616.80万元大幅好转。
- 扣除非经常性损益后的净利润为-10,146.42万元，依然为负，但较上年同期的-18,649.60万元明显改善。
- 基本每股收益为-0.0111元，较上年同期的-0.3619元亏损大幅减少。
- 加权平均净资产收益率（ROE）为-9.70%，同比增加了111.67个百分点，显示公司盈利能力大幅修复。
- 截至报告期末，公司总资产为82,392.32万元，较年初下降4.37%；归属于母公司的所有者权益为5,657.69万元，同比下降7.37%；每股净资产0.11元。
二、分子公司经营情况
- 华盛丰公司：2025年度营业收入42,359.17万元，同比增长29.55%；营业利润26.55万元，净利润-377.17万元，净资产7,648.69万元。
- 生物新材公司：2025年度营业收入1,019.76万元，同比大幅下降74.15%；营业利润-9,288.36万元，净利润-9,623.21万元，净资产为-10,379.48万元，显示经营压力极大。
三、关键影响因素与经营分析
四、可能影响股价的事项与投资者须知
- 亏损大幅收窄与资产处置收益均为重磅利好，或将提振市场信心，改善估值预期。
- 生物新材料业务持续大幅亏损值得高度关注，若无法改善，或对公司长期盈利能力构成压力。
- 公司资产负债表依然承压，生物新材子公司已出现净资产为负的局面，须警惕潜在财务风险。
- 业绩快报数据未经审计，最终数据以年度报告为准，投资者需持续关注正式年报披露。
五、风险提示
截至公告披露日，公司不存在影响本次业绩快报内容准确性的重大不确定因素。但由于本次快报数据为初步核算数据，尚未经审计，最终以公司2025年年度报告正式披露为准。敬请广大投资者注意相关风险。
免责声明：本报道仅基于山西华阳新材料股份有限公司发布的2025年度业绩快报整理，所有信息以公司正式披露为准，不构成任何投资建议。投资需谨慎。
English Version
Huayang New Materials 2025 Preliminary Annual Results: Losses Narrow Sharply, Asset Disposal Boosts Earnings
Huayang New Materials 2025 Preliminary Results: Major Loss Reduction, Substantial Asset Disposal Gains
Shanxi Huayang New Materials Co., Ltd. (600281) released its 2025 preliminary annual results on April 4, 2026, providing investors with a detailed update on its latest financial and operating performance.
1. Key Highlights and Major Financial Data
- Double-digit revenue growth: 2025 revenue reached RMB 451.36 million, up 16.67% year-on-year.
- Significant narrowing of losses: Net profit attributable to shareholders was -RMB 5.70 million, a sharp improvement from -RMB 186.17 million last year.
- Net profit after deducting non-recurring gains and losses was -RMB 101.46 million, also much improved from -RMB 186.50 million a year ago.
- Basic EPS was -RMB 0.0111, compared to -RMB 0.3619 in the previous year.
- Weighted average ROE was -9.70%, up 111.67 percentage points year-on-year, showing a significant rebound in profitability.
- At the end of the period, total assets were RMB 823.92 million (down 4.37%), equity attributable to shareholders was RMB 56.58 million (down 7.37%), and net assets per share were RMB 0.11.
2. Subsidiary Performance Breakdown
- Huashengfeng Co.: 2025 revenue was RMB 423.59 million, up 29.55%; operating profit RMB 0.27 million; net loss RMB 3.77 million; net assets RMB 76.49 million.
- Biomaterials Co.: 2025 revenue was RMB 10.20 million, down 74.15%; operating loss RMB 92.88 million; net loss RMB 96.23 million; net assets negative at -RMB 103.79 million, indicating severe operating pressure.
3. Key Business Drivers and Analysis
4. Price-Sensitive Issues and Investor Alerts
- Sharp narrowing of loss and sizable asset disposal gains are strong positives for the stock, likely to boost market sentiment and valuation expectations.
- Persistent heavy losses in the biomaterials segment warrant close scrutiny and, if not resolved, could undermine long-term profitability.
- Balance sheet remains under pressure; the biomaterials subsidiary’s negative net assets pose financial risk.
- Preliminary results are unaudited; final figures will be confirmed in the annual report. Investors should monitor for further updates.
5. Risk Warning
As of the announcement date, there are no significant uncertainties affecting the accuracy of this earnings report. However, the data is preliminary and unaudited. Investors are urged to refer to the formal 2025 annual report for final and accurate data, and to be mindful of related risks.
Disclaimer: This article is based solely on the company’s preliminary earnings report. All information is subject to the formal disclosures in the 2025 annual report and does not constitute investment advice. Please exercise caution and due diligence.
View 华阳新材 Historical chart here
